LifeMD (NASDAQ:LFMD) Earns Overweight Rating from Cantor Fitzgerald

LifeMD (NASDAQ:LFMD)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a report released on Tuesday,Benzinga reports. They presently have a $15.00 target price on the stock. Cantor Fitzgerald’s target price points to a potential upside of 159.97% from the company’s previous close.

LFMD has been the topic of a number of other research reports. KeyCorp lowered their price target on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Lake Street Capital began coverage on shares of LifeMD in a report on Tuesday, December 10th. They issued a “buy” rating and a $12.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of LifeMD in a report on Monday, November 11th. Finally, Mizuho began coverage on shares of LifeMD in a report on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.43.

LifeMD Stock Up 3.6 %

Shares of NASDAQ LFMD opened at $5.77 on Tuesday. LifeMD has a twelve month low of $3.99 and a twelve month high of $12.88. The stock’s 50 day moving average price is $5.67 and its 200-day moving average price is $5.38. The company has a market capitalization of $249.91 million, a PE ratio of -9.02 and a beta of 1.50.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings results on Monday, March 10th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.02. The company had revenue of $64.26 million during the quarter, compared to the consensus estimate of $57.43 million. As a group, research analysts expect that LifeMD will post -0.56 EPS for the current fiscal year.

Insider Buying and Selling at LifeMD

In other news, CEO Justin Schreiber sold 25,000 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $5.19, for a total value of $129,750.00. Following the transaction, the chief executive officer now owns 2,703,715 shares of the company’s stock, valued at approximately $14,032,280.85. This represents a 0.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 15.97% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in LFMD. Los Angeles Capital Management LLC increased its holdings in shares of LifeMD by 852.6% in the third quarter. Los Angeles Capital Management LLC now owns 121,585 shares of the company’s stock worth $637,000 after purchasing an additional 108,822 shares during the period. Royce & Associates LP increased its holdings in shares of LifeMD by 14.6% in the third quarter. Royce & Associates LP now owns 901,041 shares of the company’s stock worth $4,721,000 after purchasing an additional 114,710 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of LifeMD by 6.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 765,916 shares of the company’s stock worth $4,013,000 after purchasing an additional 48,201 shares during the period. Intech Investment Management LLC bought a new position in shares of LifeMD in the third quarter worth $54,000. Finally, Integrated Investment Consultants LLC bought a new position in shares of LifeMD in the third quarter worth $129,000. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.